Repligen Corporation (RGEN)

Currency in USD
143.64
+2.41(+1.71%)
Closed·
144.87+1.27(+0.88%)
·

RGEN Earnings

Latest Release
Jul 28, 2026
EPS / Forecast
0.54 / 0.45
Revenue / Forecast
204M / 201.47M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
09/2026--/0.473--/206.06M----Free Sign Up
06/20260.540/0.450204.00M/201.47M+20%+1.26%Free Sign Up
03/20260.480/0.380194.00M/192.05M+26.32%+1.02%Free Sign Up
12/20250.490/0.440197.91M/192.89M+11.36%+2.6%Free Sign Up
09/20250.460/0.420188.81M/181.78M+9.52%+3.87%Free Sign Up
06/20250.370/0.390182.00M/175.35M-5.13%+3.79%Free Sign Up
03/20250.390/0.350169.17M/163.40M+11.43%+3.53%Free Sign Up
12/20240.440/0.410168.00M/167.67M+7.32%+0.2%Free Sign Up
09/20240.430/0.330155.00M/153.22M+30.3%+1.16%Free Sign Up
06/20240.330/0.330154.00M/154.11M0%-0.07%Free Sign Up

All numbers in USD

Repligen Corporation Earnings Call Summary for Q2/2026

  • Repligen Q2 adjusted EPS of $0.54 beat estimates by 20%; revenue rose 12% YoY to $204M, topping forecasts by $2.53M amid strong demand.
  • Company raised FY2026 guidance: revenue $813M-$834M (10.5%-13.5% organic growth), adjusted EPS $2.03-$2.09, operating margin 15.7%-16.0%.
  • Proteins segment surged 50%, analytics grew 30%+; filtration remained weak with mid-single-digit growth expected due to Polymem sale and headwinds.
  • Shares jumped 6.21% premarket to $139.20; company delivered 12th consecutive quarter meeting or beating expectations, signaling sustained execution.
  • BioLife acquisition expected to close Q4, expanding cell therapy strategy; management noted Q3 margins will be lowest of year due to product mix.
Last Updated: 07/28/2026, 09:16 PM
Read Full Transcript

FAQ

What Is Repligen's Earnings Per Share (TTM)?

The Repligen EPS (TTM) is 0.74.

When Is The Next Repligen Earnings Date?

Repligen will release its next earnings report on Nov 03, 2026.

What Is Repligen’s Revenue Forecasts For Upcoming Quarters?

Repligen’s revenue forecast is 206.06M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.